| Date | Title | Description |
| 30.07.2024 | Kestra Medical and T. Rowe Price: Pioneering Innovations in Healthcare and Sustainable Finance | In the ever-evolving landscape of healthcare and finance, two companies are making waves. Kestra Medical Technologies is redefining cardiac care with its innovative wearable devices. Meanwhile, T. Rowe Price is spearheading sustainable inve... |
| 29.07.2024 | Scorpion Therapeutics: A Bold Leap in Precision Oncology | Scorpion Therapeutics is making waves in the world of cancer treatment. With a recent $150 million Series C funding round, the Boston-based biotech is poised to redefine the landscape of precision oncology. This funding is not just a financ... |
| 29.07.2024 | Kestra Medical: Wearable Cardioverter Defibrillator Company Closes $196 Million In Funding | Kestra Medical Technologies (a privately held wearable medical device and digital healthcare company) announced an oversubscribed $196 million funding round to support the expansion of their commercial organization and advance its goals of ... |
| 28.07.2024 | CatalYm's $150 Million Bet on Cancer Resistance: A New Dawn in Immunotherapy | In the relentless battle against cancer, CatalYm has emerged as a beacon of hope. The Munich-based company recently secured $150 million in Series D funding, a significant leap forward in its mission to combat cancer therapy resistance. Thi... |
| 27.07.2024 | CatalYm: Cancer Therapy Resistance Mechanism Company Raises $150 Million In Series D | CatalYm announced the completion of a $150 million Series D financing. The oversubscribed funding round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund, Omega Funds and Gilde... |
| 27.07.2024 | Scorpion Therapeutics Raises $150 Million For Enhancing Clinical-Stage Precision Oncology Pipeline | Scorpion Therapeutics, a clinical-stage oncology company dedicated to transforming the lives of cancer patients by redefining the frontier of precision oncology, announced the closing of a $150 million Series C financing. The funding was co... |
| 25.07.2024 | Canadian Startups Surge: Clio and Third Arc Bio Lead the Charge**
** | ** In the world of startups, the spotlight often shines brightest on Silicon Valley. Yet, this week, Canadian startups have taken center stage, proving that innovation knows no borders. Two companies, Clio and Third Arc Bio, have made headl... |
| 23.07.2024 | Third Arc Bio Launches with Oversubscribed $165 Million Series A Financing to Deliver Superior Biologics for Solid Tumors and Inflammatory & Immunology (I&I) Diseases | -- Company formed and originally seeded by Omega Funds, Series A financing with exceptional syndicate led by Vida Ventures
-- World-class leadership team led by Peter F. Lebowitz, MD, PhD, Sanjaya Singh, PhD, and Joe Erhardt, PhD, well-posi... |
| 23.07.2024 | Third Arc Bio launches with $165M to address unmet needs in oncology and autoimmunity | The company was founded by executives from Johnson & Johnson
Third Arc Bio is a company that says its on mission to deliver transformational therapies for solid tumors and inflammatory & immunology diseases through the use of multif... |
| 06.10.2023 | Aerium Therapeutics begins development of three in-licensed antibodies | |
| 12.01.2023 | Andera Partners backs $60 million series C for hypertension medtech SoniVie | SoniVie, an Italy and Israel-run med tech seeking to treat hypertension through the use of ultrasound, has closed a $60 million series C round to make headway toward its clinical and regulatory pipeline.
Paris-based Andera Partners led the ... |
| 09.01.2023 | SoniVie Raises $60m in Round C Financing, and Appoints New Board Members | The funds, provided by new investors and current shareholder, will be used to support the Company clinical and regulatory path towards pre-market approval of its TIVUS™ technology for the treatment of hypertension
TEL AVIV, Israel, Jan. 9, ... |
| 13.04.2022 | CDR-Life Closes $76 million Series A Funding | |
| 20.12.2021 | Omega Funds Closes Fund VII, at $650M | Omega Funds, a Boston, MA-based international healthcare venture capital firm focused on delivering impactful medicines to patients, closed its seventh fund with $650m in limited partner capital commitments.
The new fund, Omega Fund VII, L.... |
| 17.12.2021 | Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies | BOSTON, Dec. 17, 2021 /PRNewswire/ -- Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced it has closed its seventh and largest fund with $650 million i... |
| 14.10.2021 | Rectify Pharmaceuticals Launches with $100 Million Series A Financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund | Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics that restore ABC transporter function, today announced it has closed a $100 million Series A... |
| 16.09.2021 | Anjarium Biosciences Raises CHF 55.5 Million Series A Financing | |
| 14.09.2021 | Vanqua Bio Launches with $85 Million Series B Financing and a Mission to Vanquish Neurodegenerative Diseases | – Novel drug-development approach combines advanced insights into critical neuronal cell pathways with cutting-edge assays to enable next-generation therapies –
– Lead program targets Parkinson’s disease and all forms of Gaucher disease –
C... |
| 27.07.2021 | Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X | • Funding propels Artios’ ability to progress beyond synthetic lethality and to continue the exploitation of the full spectrum of oncology vulnerabilities presented by the DNA Damage Response through deployment of Artios’ DDR-based platform... |
| 27.07.2021 | IP : Artios Pharma Ltd - Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X | • Funding propels Artios' ability to progress beyond synthetic lethality and to continue the exploitation of the full spectrum of oncology vulnerabilities presented by the DNA Damage Response through deployment of Artios' DDR-based platform... |
| 05.01.2021 | Ikena Oncology Closes $120 Million Series B Financing Led by Omega Funds | BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc., a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven cancer therapies, today announces the closing of $120 million in an oversubscribed Series B... |
| 05.01.2021 | Ikena Oncology Closes $120 Million Series B Financing Led by Omega Funds | Ikena Oncology, Inc. (“Ikena”), a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven cancer therapies, today announces the closing of $120 million in an oversubscribed Series B financing. The... |
| 05.01.2021 | Ikena Oncology Closes $120 Million Series B Financing Led by Omega Funds | - |
| 16.10.2020 | Chord Therapeutics launches with USD 16 million Series A financing | |
| 16.10.2020 | Chord Therapeutics launches with USD 16 million Series A financing | Chord Therapeutics, a clinical stage biopharmaceutical company developing drugs for rare diseases, today announces the closing of a USD16 million Series A financing exclusively from leading healthcare investor Omega Funds. In conjunction wi... |
| 20.02.2020 | Spruce Biosciences Raises $88 Million in Series B Financing, co-led by Omega Funds and Abingworth | - |
| 19.02.2020 | Spruce Biosciences Raises $88 Million in Series B Financing, co-led by Omega Funds and Abingworth | – Proceeds to advance development of Tildacerfont in Congenital Adrenal Hyperplasia and other indications
– Existing Investors Novo Holdings and RiverVest Venture Partners support the deal with new Investors HealthCap, Rock Springs Capital... |
| 11.12.2019 | Omega Funds Secures $438M for Sixth Fund to Invest in the Future of Medicine | Omega Funds, a Boston, MA-based investment firm focused on backing companies delivering impactful medicines to patients, closed Omega Fund VI, L.P., with $438 million in capital commitments.
With Fund VI, the firm will continue to execute o... |
| 28.10.2019 | Oncology Start-Up Nuvation Bio Closes $275 Million Series A Financing Led by Omega Funds | Nuvation Bio, Inc., a stealth biotechnology company developing proprietary therapies focused on oncology, announces the closing of $275 million in an oversubscribed Series A financing. The round was led, structured and syndicated by Omega F... |
| 22.05.2017 | Anaconda Biomed Secures 15M Euro in Series A Financing Led by Ysios Capital, Innogest Capital and Omega Funds | Anaconda Biomed, a pre-clinical stage medical device company focused on the development of the next generation of neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS), today announces it has closed a Series A financin... |
| - | Spruce Biosciences Raises $88 Million in Series B Financing, co-led by Omega Funds and Abingworth | – Proceeds to advance development of Tildacerfont in Congenital Adrenal Hyperplasia and other indications
– Existing Investors Novo Holdings and RiverVest Venture Partners support the deal with new Investors HealthCap Partners, Rock Spring... |
| - | Wow of the week: 3-D scanner maps ear canal to improve hearing aid development (video) | In a move to disrupt the hearing industry, a medical device company has launched a handheld 3-D scanner to map the inner ear to improve the quality of hearing aids. It’s also offering the platform to any hearing aid maker that wants it.
The... |